Welcome to our dedicated page for Beta Bionics SEC filings (Ticker: BBNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Beta Bionics, Inc. (Nasdaq: BBNX) provides access to the company’s official U.S. Securities and Exchange Commission disclosures. As a commercial-stage medical device company focused on the iLet Bionic Pancreas for insulin-requiring people with diabetes, Beta Bionics uses its filings to report financial results, operational metrics, and significant corporate events.
Investors can review current reports on Form 8-K, which the company uses to announce quarterly financial results and other material information. Recent 8-K filings reference press releases detailing net sales, gross margin, operating expenses, net loss, cash and investment balances, and non-GAAP measures such as adjusted EBITDA, along with reconciliations to the most directly comparable GAAP measures.
Filings also describe operational indicators that are central to Beta Bionics’ business, including installed customer base, new patient starts, and the mix of reimbursement between the Durable Medical Equipment channel and the Pharmacy Benefit Plan channel. These disclosures help readers understand how the iLet Bionic Pancreas is being adopted and reimbursed in practice.
In addition, the company has filed 8-Ks to furnish investor and analyst presentations and to summarize “real-world” iLet data. These materials discuss changes from baseline HbA1c to glucose management indicator, hypoglycemia metrics, and outcomes for users transitioning from multiple daily injections or competitive hybrid-closed loop systems, as well as analyses of usage patterns such as “fully-closed loop” operation.
Through its registration of common stock on the Nasdaq Global Market under the symbol BBNX, Beta Bionics is subject to ongoing reporting obligations. On this page, AI-powered tools can assist by summarizing lengthy filings, highlighting key figures and definitions, and helping readers navigate topics such as non-GAAP metrics, risk factor discussions, and descriptions of clinical and real-world data included in exhibits.
For anyone researching BBNX, the SEC filings page is a primary source for understanding the company’s reported financial condition, regulatory communications, and the detailed context behind its press releases and investor materials.
Beta Bionics (BBNX) insider activity: A director reported open-market sales of common stock on 10/31/2025 made under a Rule 10b5-1 plan adopted on July 31, 2025. The filings show two transactions: 1,368 shares sold at a weighted average price of $26.8474 (with individual sale prices ranging from $26.27 to $27.24), and 38 shares sold at $27.70.
Following these sales, the reporting person beneficially owned 9,841 shares, held directly. The form notes that full breakdowns of the number of shares sold at each separate price within the weighted-average transaction are available upon request.
Beta Bionics (BBNX) director reported open-market sales on 10/31/2025 under a Rule 10b5-1 plan adopted July 31, 2025. Two transactions were disclosed: 1,287 shares at a weighted average price of $26.8588 (range $26.27–$27.22) and 119 shares at a weighted average price of $27.4502 (range $27.32–$27.57).
Following these trades, the reporting person directly beneficially owns 9,841 shares. The filing notes full trade breakdowns by price increment are available upon request.
Beta Bionics (BBNX) reported Q3 results showing rapid top-line growth as it scales commercialization of the iLet Bionic Pancreas. Net sales were $27.3 million for the quarter, up from $16.7 million a year ago, driven by both device and recurring single‑use products across durable medical equipment and pharmacy channels. Gross profit reached $15.1 million, reflecting higher volumes.
Operating expenses rose with commercialization: research and development $8.2 million, sales and marketing $16.0 million, and general and administrative $7.9 million. The company posted a net loss of $14.2 million in Q3 and $59.7 million for the nine months. Loss per share was $0.33 on 43.6 million weighted‑average shares.
Liquidity strengthened post‑IPO. As of September 30, 2025, cash and cash equivalents were $38.5 million, short‑term investments $190.2 million, and long‑term investments $45.3 million. Total assets were $330.0 million and stockholders’ equity was $294.8 million. In January 2025, the company completed an IPO with approximately $190.4 million in net proceeds and a $15.6 million concurrent private placement; preferred stock and certain warrants converted to common. Shares outstanding were 44,024,631 as of October 24, 2025.
Beta Bionics, Inc. reported that it issued a press release announcing financial results for the third quarter ended September 30, 2025. The release is included as Exhibit 99.1.
The information under Item 2.02 is furnished and is not deemed “filed” under the Exchange Act or incorporated by reference unless expressly stated otherwise.
Stephen Feider, Chief Financial Officer of Beta Bionics, Inc. (BBNX), reported insider transactions dated 10/03/2025. He acquired 4,982 shares on that date through exercise of an employee stock option with an exercise price of $5.10, bringing his beneficial ownership to 49,023 shares immediately after the acquisition. On the same date he sold 3,828 shares at a weighted average price of $21.5172 and 1,154 shares at a weighted average price of $22.2778, executed pursuant to a Rule 10b5-1 plan adopted on 05/15/2025. After these transactions his reported beneficial ownership is 44,041 shares. The option shares vest in 48 equal monthly installments measured from 09/14/2023.
Beta Bionics (BBNX) reported an insider transaction by its Chief Financial Officer on 10/01/2025. The CFO exercised employee stock options for 15,018 shares at an exercise price of $5.10 per share, then sold 14,918 shares at a weighted average price of $20.76 and an additional 100 shares at $21.08, pursuant to a Rule 10b5-1 trading plan adopted on May 15, 2025.
Following these transactions, the officer beneficially owned 44,041 shares directly. The option exercise related to an award covering 15,018 underlying shares that vests in 48 equal monthly installments measured from September 14, 2023 and carries an expiration date of September 13, 2033. After the reported activity, 74,677 derivative securities (employee stock options) were beneficially owned.
Beta Bionics, Inc. Form 144 shows a proposed sale of 4,982 common shares through Merrill Lynch on 10/03/2025 with an aggregate market value of $108,076.24. The filing identifies prior insider sales by Stephen Feider in the past three months, including a 15,018-share trade on 10/01/2025 that generated $311,836.91 and other sales dated 09/08/2025, 09/05/2025, 08/22/2025, and 08/19/2025. The securities to be sold were acquired via stock options on 10/03/2025 and the filing indicates payment was made in cash on 10/01/2025. The seller represents there is no undisclosed material adverse information. The filing supplies transaction details but does not include the issuer's SEC file number, issuer address, or the filer CIK.
Insider sale notice for Beta Bionics, Inc. (BBNX): The filer reports a proposed sale of 15,018 common shares with an aggregate market value of $311,836.91 to be executed on 10/01/2025 on NASDAQ. The filing states the shares were acquired on 10/01/2025 through stock options granted by the issuer and paid for in cash.
The filing also discloses four recent transactions by the same seller totaling 20,000 shares sold between 08/19/2025 and 09/08/2025 with combined gross proceeds of $331,831.80. The filer certifies no undisclosed material adverse information and includes broker details for the planned sale.
Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander disclosed a shared, non‑sole beneficial ownership of 2,286,728 shares of Beta Bionics, Inc. common stock, representing 5.3% of the class. The filing on a Schedule 13G indicates the stake is reported under passive ownership rules, with no sole voting or dispositive power claimed and shared voting and dispositive power of 2,286,728 shares. Addresses and citizenships of the reporting persons are provided and a Joint Filing Agreement is attached.
Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander disclosed a shared, non‑sole beneficial ownership of 2,286,728 shares of Beta Bionics, Inc. common stock, representing 5.3% of the class. The filing on a Schedule 13G indicates the stake is reported under passive ownership rules, with no sole voting or dispositive power claimed and shared voting and dispositive power of 2,286,728 shares. Addresses and citizenships of the reporting persons are provided and a Joint Filing Agreement is attached.
Stephen Feider, Chief Financial Officer of Beta Bionics, Inc. (BBNX), exercised employee stock options and completed an offsetting sale on 09/08/2025. He exercised 9,900 options with an exercise/conversion price of $5.10 per share, resulting in acquisition of 9,900 shares underlying the option.
The same day Mr. Feider sold 9,900 shares pursuant to a Rule 10b5-1 plan adopted May 15, 2025, at a weighted average sale price of $21.12648 per share (range $21.00–$21.2933). After these reported transactions he beneficially owned 44,041 shares of common stock and reported 89,695 derivative securities beneficially owned.